Please login to the form below

Not currently logged in
Email:
Password:

Boehringer/ Elan antibody deal

Boehringer Ingelheim has announced a partnership with Elan to develop and manufacture antibody-based therapeutics

Boehringer Ingelheim has announced a partnership with Ireland-based Elan to develop and manufacture antibody-based therapeutics.

German drugmaker, Boehringer said the global deal will see Elan lead the discovery and clinical development of antibodies, with Boehringer to take over the clinical manufacturing and regulatory filing.

"The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim's process development and production capabilities," said Dr Johannes Roebers, head of biologic strategy, planning and operations at Elan.

Elan is a biotech with a focus on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.

Financial details were not disclosed.

The partnership will make use of Boehringer's High Expression Technology (BI HEX) platform, which aims to speed up development times for biological entities, such as antibodies.

"This is a first step in our new strategy engaging our technology platforms at a very early stage in product development," said Simon Sturge, corporate senior vice president of Boehringer's biopharmaceutical division.

Dr Dale Schenk, chief scientific officer, Elan, said the partnership would increase the productivity and potential of the company's development plans for antibodies: "These programmes are broad in scope and are innovative across technology, targets and possible disease application."

10th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Publicis Resolute

Publicis Resolute provides real-life practical solutions to your issues, without fuss or fluff. We are an experienced team with a...

Latest intelligence

Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...
Generation Z
The roaring ‘20s and Generation Z
How a new generation will shape pharma comms this decade...

Infographics